A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.
Marginal Zone Lymphoma
DRUG: Rituximab|DRUG: Venetoclax
complete response rate (CRR), Will be evaluated in this study using the RECIL criteria., 2 years
overall response rates (ORR), Overall response rate (ORR) will be measured as the number of patients that achieve a PR or CR per RECIL criteria., 2 years
This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.